Jun 11, 2007 by Brian LawlerEndo Shows FrovaEndo releases more clinical trial results for one of its compounds.
Jun 8, 2007 by Brian LawlerThis Stupid Mistake Cost Me More Than $20,000Going without health-care coverage can spell disaster for your finances.
Jun 8, 2007 by Brian LawlerA Conversation With AlexzaThe Fool sits down with Alexza's president and CEO.
Jun 8, 2007 by Brian LawlerLilliputian Attack on Lilly?Eli Lilly loses a pair of patent cases over its top compound.
Jun 7, 2007 by Brian LawlerAre You Ignoring the Most Exciting Stocks?Never considered drug stocks? You're missing some of the market's best investments.
Jun 6, 2007 by Brian LawlerIs Telik Insane?Shares of Telik fall after the FDA puts a halt to trials with its lead drug.
Jun 5, 2007 by Brian LawlerDendreon Gets Its FundingDendreon does a financing to secure its near-term future.
Jun 5, 2007 by Brian LawlerAnother Buyout in the Works for AOB?AOB announces a very large debt offering.
Jun 5, 2007 by Brian LawlerExelixis PresentsExelixis presents data from 2 of its top drug candidates at ASCO.
Jun 4, 2007 by Brian LawlerIs AtheroGenics Grasping at Straws?AtheroGenics announces the path forward for its lead drug.
Jun 4, 2007 by Brian LawlerIs Introgen Stringing Investors Along?One development-stage drugmaker not to own.
Jun 4, 2007 by Brian LawlerProgenics Is on the ClockProgenics' marketing application for its lead compound gets accepted for review.
Jun 1, 2007 by Brian LawlerWyeth's On a RollThe FDA approves a kidney cancer fighting compound from Wyeth.
Jun 1, 2007 by Brian LawlerA Preview of the ASCO WarsA preview of some of the biopharmas presenting at the American Society of Clinical Oncology conference.
Jun 1, 2007 by Brian LawlerDendreon Gains. Why?Shares of Dendreon rise after it announces already expected news.
Jun 1, 2007 by Brian LawlerEncysive Invades CanadaIts lead compound gets marketing approval in the Great White North.
Jun 1, 2007 by Brian LawlerThe Generic Cracks Open for PfizerPfizer loses a patent case over its top compound.
May 31, 2007 by Brian LawlerDueling Fools: Eli Lilly BearThe bearish argument against investing in Eli Lilly
